Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zeranol is a synthetic nonsteroidal estrogen of the resorcylic acid lactone group, structurally related to mycoestrogens produced by Fusarium fungi. It acts as a potent estrogen receptor agonist, being 3–4 times more active than the related compound zearalenone. Zeranol is primarily used as an anabolic agent and growth promoter in veterinary medicine, especially for livestock such as beef cattle. It is approved for this use in several countries under various brand names (notably Ralgro by Merck Animal Health). Zeranol may also be found as a contaminant in fungus-infected crops due to its origin from Fusarium species. Its mechanism of action involves binding and activating estrogen receptors, leading to anabolic and growth-promoting effects[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zeranol.